Trial Profile
An open label multi facilities cooperation randomized control trial to verify renoprotective effects of improvement in postprandial hyperglycemia in diabetic nephropathy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Mitiglinide (Primary) ; Glimepiride
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 11 Jan 2019 Status changed from recruiting to completed.
- 09 Nov 2011 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by University Hospital Medical Information Network - Japan.
- 25 Jan 2011 New trial record